FDA granted accelerated approval for Regeneron's drug, which is expected for MM cases in the US in 2025.
1 report, 0 independent
Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted accelerated approval for Regeneron's drug, which is expected for MM cases in the US in 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Regeneron Pharmaceuticals
American pharmaceutical company
- FDA
Related events
- The FDA recommended advancement for a new drug application submitted by a company.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- An unnamed company secured regulatory approval in July 2025, leading to a $2.5 million milestone reported today.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
Coverage
Newest first; wire copies grouped- Unknown outlet